- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer COVID vaccine approved for kids under 5 in Canada
It's the second vaccine approved for that age group after Health Canada approved Moderna's Spikevax in July.
Ottawa: Health Canada has approved Pfizer's Covid-19 vaccine to immunise children under the age of five.
The federal health department updated information of the approved vaccines on its website saying that available data supported the effectiveness and safety of the vaccine in preventing Covid in the age group of six months through four years, reports Xinhua news agency.
The benefit-risk profile of the vaccine was considered favourable in that age group for use as a 3-dose primary series with two doses given three weeks apart followed by a third dose given at least eight weeks after the second dose.
Read also: COVID drug: Zenara Pharma unveils generic of Pfizer Paxlovid at Rs 5,200 per box in India
It's the second vaccine approved for that age group after Health Canada approved Moderna's Spikevax in July.
Last week, Health Canada approved an adapted version of the Moderna Spikevax COVID-19 vaccine, known as a bivalent vaccine, to target both the original SARS-CoV-2 virus and the Omicron (BA.1) variant as a booster dose in individuals aged 18 and above.
Read also: Moderna COVID vaccine SPIKEVAX gets nod in Canada for children aged 6 months to 5 years
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.